The advent of PSMA-targeted imaging agents, particularly Gallium-68-labeled tracers (68Ga-PSMA), has revolutionized prostate cancer diagnostics, first gaining traction in Europe about a decade ago [5]. This evidence concerns the gene FOLH1 and Familial prostate cancer.